DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Yonghan He(University of Florida), Daohong Zhou(The University of Texas at San Antonio Health Science Center)

Journal of Hematology & Oncology

July 16, 2020

10.1186/s13045-020-00928-9

Cited by 129

Related Papers

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

|Nature Communications|2021|145

Ursolic Acid Inhibits Adipogenesis in 3T3-L1 Adipocytes through LKB1/AMPK Pathway

|PLoS ONE|2013|142

Senescence-associated hyper-activation to inflammatory stimuli in vitro

|Aging|2021|57

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

|Cell Death Discovery|2023|43

A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice

|Nature Aging|2025|37